# To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

> **NCT07370818** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Onconic Therapeutics Inc.** · enrollment: 81 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** JPI-547
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07370818
- **Lead sponsor:** Onconic Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-27
- **Primary completion:** 2029-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07370818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07370818, "To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07370818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*